Takeda announces approval of hyqvia® 10% s.c. (subcutaneous) injection set in japan for patients with agammaglobulinemia or hypogammaglobulinemia

Osaka, japan & cambridge, mass.--(business wire)--takeda (tse:4502/nyse:tak) today announced that the japanese ministry of health, labour and welfare has approved the use of hyqvia® [immune globulin infusion 10% (human) with recombinant human hyaluronidase] in patients with agammaglobulinemia or hypogammaglobulinemia1, disorders characterized by very low or absent levels of antibodies and an increased risk of serious recurring infection caused by primary immunodeficiency (pid) or secondary immu.
TAK Ratings Summary
TAK Quant Ranking